DE69739663D1 - Pharmazeutische glutathionpräparate und methoden zu dern verabreichung - Google Patents

Pharmazeutische glutathionpräparate und methoden zu dern verabreichung

Info

Publication number
DE69739663D1
DE69739663D1 DE69739663T DE69739663T DE69739663D1 DE 69739663 D1 DE69739663 D1 DE 69739663D1 DE 69739663 T DE69739663 T DE 69739663T DE 69739663 T DE69739663 T DE 69739663T DE 69739663 D1 DE69739663 D1 DE 69739663D1
Authority
DE
Germany
Prior art keywords
administration
glutathion
preparations
pharmaceutical
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69739663T
Other languages
German (de)
English (en)
Inventor
Harry B Demopoulos
Myron L Seligman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antioxidant Pharmaceuticals Corp
Original Assignee
Antioxidant Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21874315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69739663(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antioxidant Pharmaceuticals Corp filed Critical Antioxidant Pharmaceuticals Corp
Application granted granted Critical
Publication of DE69739663D1 publication Critical patent/DE69739663D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
DE69739663T 1996-12-31 1997-12-31 Pharmazeutische glutathionpräparate und methoden zu dern verabreichung Expired - Fee Related DE69739663D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3410196P 1996-12-31 1996-12-31
PCT/US1997/023879 WO1998029101A1 (en) 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof

Publications (1)

Publication Number Publication Date
DE69739663D1 true DE69739663D1 (de) 2009-12-31

Family

ID=21874315

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739663T Expired - Fee Related DE69739663D1 (de) 1996-12-31 1997-12-31 Pharmazeutische glutathionpräparate und methoden zu dern verabreichung

Country Status (8)

Country Link
US (5) US6159500A (enExample)
EP (1) EP0957901B1 (enExample)
JP (1) JP2001507696A (enExample)
AT (1) ATE448782T1 (enExample)
AU (1) AU5620598A (enExample)
CA (2) CA2276183C (enExample)
DE (1) DE69739663D1 (enExample)
WO (1) WO1998029101A1 (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744593A (en) * 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
CA2317603A1 (en) * 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
WO2001012166A2 (en) * 1999-08-17 2001-02-22 University Of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
EP1214038A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
PT1086695E (pt) * 1999-09-21 2005-05-31 Enzo Leone Composicoes antivirais que compreendem ioimbina como principio activo
WO2001068069A2 (en) * 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
GB0008689D0 (en) * 2000-04-07 2000-05-31 Nokia Networks Oy A method and system for processing signals
EP1292309A4 (en) * 2000-04-07 2004-08-11 Sang Geon Kim PROPHYLACTIC AND THERAPEUTIC USE OF OLTIPRAZ AS AN AGENT AGAINST FIBROSIS AND CIRRUSH OF THE LIVER AND PHARMACEUTICAL COMPOSITION CONTAINING OLTIPRAZ
CA2408399A1 (en) * 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
WO2003025831A2 (en) * 2001-09-14 2003-03-27 Roke Manor Research Limited Tag and tagging system
US6726809B2 (en) * 2001-09-26 2004-04-27 Albany International Corp. Industrial process fabric
US20030119814A1 (en) * 2001-10-16 2003-06-26 The University Of Kansas Novel prodrugs of N-H bond-containing compounds and methods of making thereof
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
AU2002357311A1 (en) * 2001-12-18 2003-06-30 Johns Hopkins University School Of Medicine Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
US20030194453A1 (en) * 2002-04-15 2003-10-16 Coleman Henry D. Dietary supplement
US20060099239A1 (en) * 2002-04-15 2006-05-11 Coleman Henry D Dietary supplement for promoting removal of heavy metals from the body
US20040213829A1 (en) * 2002-04-15 2004-10-28 Coleman Henry D. Dietary supplement
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
US20050255129A1 (en) * 2002-05-03 2005-11-17 Luc Montagnier Treatments and methods for treatment, diagnosis and prophylaxis
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US20100316700A1 (en) * 2002-11-07 2010-12-16 Guilford F Timothy Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury
WO2004055165A2 (en) * 2002-12-13 2004-07-01 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US8283435B2 (en) 2003-02-21 2012-10-09 Metabolix, Inc. PHA adhesive compositions
JP4724111B2 (ja) * 2003-02-21 2011-07-13 メタボリックス インコーポレイティッド Ｐｈａブレンド
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN102302781A (zh) * 2003-10-15 2012-01-04 前体生物药物股份公司 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
CA2550009C (en) * 2003-12-30 2013-05-14 Metabolix, Inc. Nucleating agents
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
WO2005115173A1 (en) * 2004-05-24 2005-12-08 Ott David M Medicinal products incorporating bound organosulfur groups
JP5066448B2 (ja) 2004-09-03 2012-11-07 協和発酵バイオ株式会社 口内炎の予防または治療のための組成物および方法
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
PL1817006T3 (pl) * 2004-11-07 2013-03-29 F Timothy Guilford Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
CN101084003A (zh) * 2004-12-21 2007-12-05 重症救护联络公司 治疗性营养组合物或联合药物及其使用方法
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
WO2006081363A2 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
US8232240B2 (en) * 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
EP1906930A2 (en) * 2005-07-13 2008-04-09 Al Czap Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
US20110112032A1 (en) * 2005-09-12 2011-05-12 Ming-He Huang Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases
GB2430364A (en) * 2005-09-22 2007-03-28 Carl Ernest Alexander Soft agar bolus for oral drug delivery
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
JP5303465B2 (ja) 2006-10-05 2013-10-02 イカリア， インコーポレイテッド 液体カルコゲナイド組成物ならびにそれを製造および使用する方法
US20080227846A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
EP2170356A1 (en) 2007-06-25 2010-04-07 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
GB0722923D0 (en) * 2007-11-22 2008-01-02 Uhi Millennium Inst Improved anti-platelet compositions
JP5406049B2 (ja) * 2008-02-05 2014-02-05 協和発酵バイオ株式会社 グルタチオンの保存安定性向上方法
JP5499714B2 (ja) * 2008-02-15 2014-05-21 味の素株式会社 腸管免疫賦活剤
WO2010044875A2 (en) * 2008-10-16 2010-04-22 Novan, Inc. Nitric oxide releasing particles for oral care applications
JP5208028B2 (ja) * 2009-03-16 2013-06-12 学校法人帝京大学 Ｅｄ評価方法
US8313456B2 (en) * 2009-06-30 2012-11-20 Palo Alto Research Center Incorporated Drug-transfer device, drug-delivery system incorporating the same, methods of fabricating the same, and methods of enabling administration of a drug
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
US20110086234A1 (en) * 2009-10-13 2011-04-14 Nathan Stasko Nitric oxide-releasing coatings
WO2011091807A1 (en) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant and glutathione for treatment of cancer
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
AU2013219258B2 (en) * 2012-02-15 2017-05-25 Kyowa Hakko Bio Co., Ltd. Agent for preventing or ameliorating vascular endothelial malfunction
US20130323324A1 (en) * 2012-06-01 2013-12-05 Franco Cavaleri Vanadium and vanadyl amino acid complexes
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof
US9475930B2 (en) 2012-08-17 2016-10-25 Metabolix, Inc. Biobased rubber modifiers for polymer blends
JP6469568B2 (ja) * 2012-09-28 2019-02-13 協和発酵バイオ株式会社 グルタチオンを含有する免疫増強剤
US20140100283A1 (en) * 2012-10-05 2014-04-10 Atlantic Pro Nutrients, Inc. dba XYMOGEN Method to Increase Absorption and Bioavailability of Oral Glutathione
ES2940822T3 (es) 2013-01-21 2023-05-11 Kyowa Hakko Bio Co Ltd Agente elevador de la concentración de óxido nítrico
WO2014194220A1 (en) 2013-05-30 2014-12-04 Metabolix, Inc. Recyclate blends
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
PT3104939T (pt) 2014-02-10 2024-07-17 Fred Hutchinson Cancer Center Tratamento de ataque cardíaco e lesão isquémica com iodeto de sódio
CA2961380A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
CA3081693C (en) * 2014-10-09 2022-01-11 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the reduction of heavy metal toxicity
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
WO2017091737A1 (en) * 2015-11-25 2017-06-01 Molecular Defenses Corporation Pharmaceutical formulations
US10702590B2 (en) * 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US20180008665A1 (en) * 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
US11602555B2 (en) 2016-11-17 2023-03-14 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
EP3733197A1 (en) * 2019-04-30 2020-11-04 Stephen N. Pitcher Anaerobic antioxidant composition
JP2022074429A (ja) * 2020-11-04 2022-05-18 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
EP4289444A1 (en) * 2021-02-02 2023-12-13 Nesa LLC Anti-viral agent
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액
IT202200007229A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007232A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
WO2023199241A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof
IT202200007238A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
PE20251171A1 (es) * 2022-04-12 2025-04-23 Uriach Italy S R L Composicion que comprende n-acetilcisteina, vitamina d y preferentemente glutation, usos de la misma y composiciones farmaceuticas y nutraceuticas de la misma
KR102602347B1 (ko) * 2022-05-09 2023-11-15 천현수 위장내 발암성 엔-니트로사민 생성 억제 및 장내 산화질소 생성 촉진용 천연 조성물 및 이의 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
FR2461002A1 (fr) 1979-07-13 1981-01-30 Inst Nat Sante Rech Med Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede
US4381307A (en) 1980-10-31 1983-04-26 Merck & Co., Inc. Soft tertiary amine esters of bio-affecting carboxylic acids
US4477435A (en) 1981-05-19 1984-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for regenerating corneal epithelium
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4454125A (en) 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4534967A (en) 1982-08-03 1985-08-13 Boston Biomedical Research Institute Cell proliferation inhibitor and method of preparation
US4770877A (en) 1982-08-03 1988-09-13 Boston Biomedical Research Institute Isolation of a high molecular weight aortic endothelial cell growth inhibitor
DE3686927T2 (de) 1985-02-26 1993-03-25 Univ Johns Hopkins Neovaskularisierungsinhibitoren und deren herstellung.
JPS62169723A (ja) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5061729A (en) 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
IT1231012B (it) 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
JP2919870B2 (ja) * 1989-09-29 1999-07-19 千寿製薬株式会社 肝障害抑制剤
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ES2244529T3 (es) 1991-02-01 2005-12-16 Daiichi Suntory Pharma Co., Ltd. Composiciones antibacterianas orales y metodo para la mejora de la absorcion gastrointestinal de los antibioticos de penemo o carbapenemo.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
JPH07503010A (ja) * 1992-01-06 1995-03-30 ヘルス・メインテナンス・プログラムズ，インコーポレイテッド 薬学活性酸化防止剤含有組成物並びに該組成物を使用する血管形成後の再狭窄予防および治療方法
US5204114A (en) * 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US5840686A (en) 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US6319687B1 (en) 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
WO1995003063A1 (en) 1993-07-22 1995-02-02 Esseti S.A.S. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C. Oral pharmaceutical compositions comprising reduced glutathion
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5985926A (en) 1993-11-01 1999-11-16 Cell Therapeutics, Inc. Method for inhibiting intracellular viral replication
US5679541A (en) 1994-02-14 1997-10-21 California Institute Of Technology Programmed cell death antagonist protein
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6015665A (en) 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5929063A (en) 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5674907A (en) 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
US5681711A (en) 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
CA2221716A1 (en) * 1995-05-19 1996-11-21 New York Blood Center, Inc. Methods of use of phthalocyanines to inactivate blood borne parasites
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases

Also Published As

Publication number Publication date
JP2001507696A (ja) 2001-06-12
CA2276183C (en) 2009-06-09
WO1998029101A1 (en) 1998-07-09
US6586404B1 (en) 2003-07-01
US6159500A (en) 2000-12-12
EP0957901B1 (en) 2009-11-18
CA2276183A1 (en) 1998-07-09
CA2650204A1 (en) 1998-07-09
EP0957901A1 (en) 1999-11-24
US6204248B1 (en) 2001-03-20
AU5620598A (en) 1998-07-31
ATE448782T1 (de) 2009-12-15
EP0957901A4 (en) 2006-04-12
US6350467B1 (en) 2002-02-26
US6423687B1 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
DE69739663D1 (de) Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
Shah et al. Evaluation of orally administered highly variable drugs and drug formulations
DE3686936D1 (de) Am zielorgan wirkendes enterales abgabesystem.
CA2152062A1 (en) Enhanced Solubility Pharmaceutical Solutions
IE871584L (en) Sustained release capsule.
FI944035A0 (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
NZ503946A (en) Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
PL341055A1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CA2279522A1 (en) Biocompatible compounds for pharmaceutical drug delivery systems
CO4910114A1 (es) Formulaciones farmaceuticas para suministro de droga soste- nido
HUP9903734A2 (hu) Szabályozott felszabadulású, orális gyógyszerkészítmények és eljárás ezek előállítására
MY125662A (en) Pharmaceutical formulations containing darifenacin
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
MY132911A (en) Clear, injectable solution of an anesthetic compound
DK0652744T3 (da) Farmaceutiske midler til afgivelse af peptider gennem slimhinden
ZA963584B (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
ATE484295T1 (de) Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
ITMI921413A0 (it) Preparazioni farmaceutiche stabili di nicorandil
NO892764L (no) Medikamentell administreringsform for droevtyggere.
EP0271151A3 (en) Azumolene dosage form
DK0615444T3 (da) Peroral indgivelsesform til peptidlægemidler, især insulin
PL325242A1 (en) Method of obtaining solid drug administration forms for very low dosage drugs

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee